Sign in

CIK 0001157601 · Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(267) 824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
  1. 4 Grant or award Director acquired 714 shares (grant or award)
  2. 4 Grant or award Director acquired 714 shares (grant or award)
  3. 4 Grant or award Director acquired 714 shares (grant or award)
  4. 4 Grant or award Director acquired 714 shares (grant or award)
  5. 4 Grant or award Director acquired 714 shares (grant or award)
  6. 4 Grant or award Director acquired 2,856 shares (grant or award)
  7. 4 Open-market sale Senior VP, Chief Pharma Dev. sold 1,900 shares at $280.00 ($532,000)
  8. 4 Open-market sale Senior VP, Chief Pharma Dev. sold 2,000 shares at $285.00 ($570,000)
  9. 4 Gift Director gave 84,852 shares (gift)
  10. 4 Open-market sale Senior VP, Chief Pharma Dev. sold 1,036 shares at $231.34 ($239,668)
  11. 4 Planned sale Director sold 22,489 shares at an average $212.88 ($4,787,404)
  12. 4 Planned sale Pres., R&D, and CMO sold 2,676 shares at an average $245.99 ($658,258)
  13. 4 Planned sale Director sold 26,270 shares at an average $246.19 ($6,467,491)
  14. 4 Planned sale Pres., R&D, and CMO sold 73,888 shares at an average $243.92 ($18,022,588)
  15. 4 Planned sale Director sold 73,730 shares at an average $243.93 ($17,984,804)
  16. 4 Planned sale Director sold 11,000 shares at an average $257.48 ($2,832,335)
  17. 4 Planned sale Director sold 32,489 shares at an average $252.85 ($8,214,998)
  18. 4 Planned sale Director sold 32,489 shares at an average $252.97 ($8,218,630)
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 6 of 29 · 564 filings